Kornimate/medical-research-clean huggingface dataset:
impact of enhanced daily disinfection on environmental contamination in hospital rooms

Conditions: Disinfection

Summary: the purpose of this study is to determine if enhanced daily application of disinfectant with persistent 24-hour activity decreases the environmental bioburden compared to standard practice.

the study investigator will evaluate the effectiveness of daily disinfection strategies on environmental contamination in acute care hospital rooms. the trial will be conducted in acute care hospital rooms at duke university hospital, duke regional hospital, duke raleigh hospital, and the university of north carolina medical center. in each study room, one half will be randomized to the control arm, and the other half will be randomized to one of the two intervention arms. two separate randomization steps will occur. first, each room will be randomized to intervention 1 or intervention 2. second, the half of the room to which the intervention will be applied (e.g., right vs. left) will be randomly selected. the control arm will receive no interventions. rooms randomized to the control arm will undergo routine disinfection via existing environmental services (evs) protocols. all study hospitals routinely use epa-registered disinfectants for low-level disinfection of hospital room surfaces. intervention 1 is the standard epa-registered disinfectant to each study surface and will be applied by the study team. intervention 2 is a quaternary ammonium, salt-based, 24-hour continuously active germicidal wipe (sani-24®) to each study surface and will be applied by the study team. three different methods will be used for disinfection. no changes to baseline and routine disinfection practices will occur during the study. evs employees at study hospitals will be responsible for the total room cleaning and disinfection throughout the study. tasks will be separated between study team members to maintain blinding.room contamination will be measured before the application of the interventions on study day 1 and every 24 hours for 3 subsequent days, for a total of 4 days. secondary outcomes include evaluation for epidemiologically important pathogens (eip), including me staphylococcus aureus (mrsa or mssa), extended spectrum beta-lactamase (esbl) or carbapenem-resistant enterobacteriaceae (cre) producing enterobacterales, vancomycin-resistant enterococci (vre), vancomycin-susceptible enterococci (vse), acinetobacter spp., and pseudomonas aeruginosa.

Eligibility criteria:
inclusion criteria: * adult patient admitted to the room * patient spent ≥1 night in room prior to enrollment * anticipated patient stay of ≥48 hours * on contact precautions (for any reason) and/or has positive culture for eip at the time of room admission exclusion criteria: * patient stay is expect to be \<48 hours * patient age \<18, even if on adult ward * patient admitted on respiratory precautions due to coronavirus disease (covid-19), influenza, or respiratory syncytial virus (rsv) * patient on contact precautions due to c. difficile

Keywords: disinfection contamination
intensive induction therapy followed by high dose chemo and bm transplant for mantle cell lymphoma

Conditions: Mantle Cell Lymphoma

Summary: patients with mantle cell lymphoma have a grave prognosis. they usually have an initial response to therapy, however progress early in the course of the disease and have very poor survival. we hypothesize that the emergence of drug resistance is responsible for this early failure of therapy and therefore intensive therapy at induction followed by high dose therapy immediately may produce a better outcome.

subjects will undergo an induction regimen consisting of 1 cycle of cytarabine (3 gm/m2 intravenously over 1 hour every 12 hours for 8 total doses) and mitoxantrone (10 mg/m2/d intravenously \[iv\] over 30 minutes daily on days 1, 2, and 3). this will be combined with alemtuzumab (anti-cd52 antibody) for 6-8 weeks. if, after this one cycle, subjects have not had progression of disease as noted on physical exam or radiographic scans, they will proceed to stem cell mobilization with cyclophosphamide. this will be immediately followed by high dose therapy with stem cell support. following count recovery, rituximab will be used for 8 total doses as consolidation therapy. involved field irradiation may be given post-transplant to those with localized bulky disease as well. day -6: carmustine (bcnu): 15 mg/kg (or 550 mg/m2) iv over 2 hrs. day -4: etoposide day -2: cyclophosphamide 100 mg/kg in 1 liter d5w over 2 hours.

Eligibility criteria:
inclusion criteria: * must have biopsy proven mantle cell lymphoma confirming mantle cell lymphoma. (flow cytometry, and cyclin d1 or t (11;14) tests of disease site should be done if available at some time in the patient's course before this therapy) * radiologic staging studies may be performed up to 6 weeks prior to starting therapy and not be repeated if the treating physician feels it unnecessary * no other prior malignancy is permitted except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for one year. * age \> or = to 18 years of age * for patients who are in first remission from a prior regimen, at least 3 weeks must elapse from a prior chemotherapy and at least 1 week from radiation or antibody therapy. exclusion criteria: * significant medical and/or psychiatric illness which, in the opinion of the investigators, may compromise any aspect of the planned treatment. * the patient cannot have been exposed to chemotherapy to treat any of these diseases (other than mantle cell lymphoma) for at least 3 years prior to entry on this protocol.

Keywords: intensive induction high dose chemotherapy bone marrow transplantation mantle cell lymphoma
study of concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

Conditions: Esophageal Squamous Cell Carcinoma

Summary: the phase i study is to determine the maximum tolerated dose and dose limiting toxicity of docetaxel and nedaplatin prescribed twice weekly in combination with concurrent chest radiotherapy in patients with locally advanced esophageal squamous cell carcinoma.


Eligibility criteria:
inclusion criteria: * histologically confirmed esophageal squamous cell carcinoma * inoperable stage ii-iii (ajcc/uicc; seventh edition), confirmed by contrast- enhanced computed tomography,endoscopic ultrasonography, barium esophagram, emission computed tomography and/or positron emission tomography/computed tomography. * eastern cooperative oncology group (ecog) performance status 1-2 * estimated life expectancy of at least 12 weeks * charlson comorbidity index≤4 * adequate bone marrow function: white blood cells grade 0 or 1,absolute neutrophils grade 0 or 1, platelets grade 0, haemoglobin grade 0 or 1 * adequate renal function: creatinine grade 0 or 1 * adequate liver function: serum bilirubin grade 0 or 1, alanine aminotransferase and aspartate aminotransferase \<2 times of the upper normal limit * weight loss≤15% during 6 months prior to diagnosis * forced expiratory volume second≥1l exclusion criteria: * prior history of malignancy, except for nonmelanoma skin carcinoma or cervical carcinoma in situ * previous anti-tumor therapy, including surgery, chemotherapy or radiotherapy * contraindication for chemotherapy or radiotherapy * malignant pleural or pericardial effusion * women in pregnancy or lactation period * women who has the probability of pregnancy without contraception * weight loss≥15% during 3 months prior to diagnosis * in other clinical trials within 30 days * addicted in drugs or alcohol, aids patients * uncontrollable seizure or psychotic patients without self-control ability * severe allergy or idiosyncrasy * not suitable for this study judged by researchers

Keywords: esophageal squamous cell carcinoma chemoradiotherapy docetaxel nedaplatin twice weekly
mpi predicts outcome of crc elderly patients (mpi=multidimensional prognostic index; crc=colorectal cancer)

Conditions: Colorectal Cancer; Fragility; Elderly

Summary: patients aged ≥75 year scheduled for crc surgery were studied (104 cases) and variables associated with major postoperative complications / mortality were evaluated. the importance of this report is that mpi-score resulted strongly associated with major complications and it was a primary component of an individual prediction model.

patients aged ≥75 year scheduled for crc surgery were studied (104 cases) and variables associated with major postoperative complications / mortality were evaluated. the mpi (multidimensional prognostic index)-score resulted strongly associated with major complications. also, it was a primary component of an individual prediction model (lasso model).

Eligibility criteria:
inclusion criteria: all crc patients aged ≥75 years, who were scheduled for elective surgery and able to express their consent to treatment, were considered. exclusion criteria: emergency surgery; patients aged \<75 years; patients unable to sign informed consent.
the netherlands registry of invasive coronary vasomotor function testing (nl-cft)

Conditions: Coronary Vasospasm; Coronary Microvascular Dysfunction; Non-Obstructive Coronary Atherosclerosis

Summary: the goal of this registry is to collect data on patients referred for clinically indicated coronary vasomotor function test (cft) and answer different questions on prevalence, safety and outcomes. the registry is observational. patients receive yearly online questionnaires on their anginal complaints for 5 years after their cft.


Eligibility criteria:
inclusion criteria: * referred for clinically indicated cft exclusion criteria: * not willing to provide informed consent
a study of tamiflu (oseltamivir) for seasonal prophylaxis of influenza in children.

Conditions: Influenza

Summary: this study will evaluate the safety of tamiflu, when used for the prevention of influenza in children during the flu season. children who would benefit from influenza prophylaxis when influenza is circulating in the community will receive treatment with tamiflu syrup (or capsules) 30mg-75mg once daily (dependent on body weight) for 6 weeks. safety data and influenza symptoms will be recorded throughout the study. the anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * males or females, 1-12 years of age; * candidate for seasonal prophylaxis; * negative rapid diagnostic test for influenza at baseline. exclusion criteria: * symptoms suggestive of influenza-like illness; * positive rapid diagnostic test for influenza; * antiviral treatment for influenza in 2 weeks prior to randomization.
alpha-glutathione-s-transferase (alphagst) and marina index in metabolic-dysfunction-associated-steatotic-liver-disease (masld)

Conditions: Fatty Liver

Summary: alphagst represents a liver enzyme whose serologic levels progressively increase in alcoholic and viral chronic hepatitis according to the worsening of liver fibrosis. however, its diagnostic and prognostic usefulness in metabolic-dysfunction-associated-steatotic-liver-disease has never been explored. the investigators aimed to assess the alphagst levels in metabolic-dysfunction-associated-steatotic-liver-disease patients affected by different stages of liver fibrosis, and, by using a new-designed "metabolic abnormalities related to lipids- insulin resistance-alphagst levels" (marina) index, to evaluate its role as a novel non-invasive tool in the disease staging stratification, identification of the advanced fibrosis and prediction of 5-years acute cardiovascular events occurrence. the investigators enrolled 30 ehalthy controls and 200 metabolic dysfunction-associated steatotic liver disease patients (training cohort) (trc). as a validation cohort (vlc), between january 2018 and may 2019, 60 masld patients were consecutively enrolled (validation cohort - vlc) all metabolic-dysfunction-associated- steatotic-liver-disease patients received an ultrasound-guided percutaneous liver biopsy for the disease staging. liver stiffness measurement, nafld fibrosis score, fibrosis-4, and body mass index-aspartate aminotransferase/platelet ratio-diabetes scores as well as the marina index were determined. naïve-acute cardiovascular events patients were subsequently followed up over 5 years to record acute cardiovascular events occurrence.


Eligibility criteria:
inclusion criteria: * age between 18 and 80 years * masld diagnosis exclusion criteria: * presence of chronic inflammatory diseases * acute or chronic kidney diseases * rheumatoid arthritis, systemic lupus erythematosus, or other major systemic inflammatory diseases or tumors * ongoing infections * alcohol or drug abuse history * other etiologies of chronic liver damage * previous hepatocellular carcinoma diagnosis * use of hepatoprotective drugs * decompensated liver cirrhosis (child-pugh b and child-pugh c) at the moment of the enrollment or in the previous 12 months * psychological/psychiatric problems that could have invalidated the informed consent

Keywords: metabolic dysfunction associated steatotic liver disease liver fibrosis liver cirrhosis non-invasive biomarkers cardiovascular risk
sebacia postmarket study of real-world use

Conditions: Acne Vulgaris

Summary: postmarket study of sebacia microparticles treatment during adoption into clinical use for patients with mild to moderate inflammatory acne vulgaris.


Eligibility criteria:
inclusion criteria: * mild to moderate facial inflammatory acne vulgaris (iga 2 or 3) * between 10 and 50 papules/pustules * fitzpatrick skin phototype i, ii or iii * able to provide informed consent and comply with study schedule and other requirements exclusion criteria: * moderately severe or severe acne vulgaris (iga 4 or 5) * nodulocystic acne, significant scarring or excoriation * requires oral retinoid, antibiotic or corticosteroid for acne * new or fluctuating hormone or hormone-regulating therapy * photosensitivity or allergy to gold * medical or mental health condition that would pose a risk to patient or impair treatment and evaluation
switch from calcineurin inhibitor to belatacept in pancreas transplant recipients

Conditions: Nephrotoxicity

Summary: kidney damage is a major complication of current antirejection medicines used in transplantation. an increasing number of brittle diabetics are successfully receiving a pancreas transplant. one of the challenges following pancreas transplant is that a patient can develop kidney damage from one of their antirejection medicines, tacrolimus. the objective of this study is to substitute a new antirejection medicine which does not cause kidney damage, belatacept for tacrolimus in patients that have developed signs of tacrolimus related kidney damage to slow the progression of kidney disease.

nephrotoxicity is a major complication of current immunosuppression regimens used in transplantation. pancreas transplantation has been increasedly performed to manage labile diabetes mellitus during the last few decades and survival rates of pancreatic grafts are improving. one of the challenges that is faced following pancreas transplantation alone are pathologic changes from diabetes frequently seen in native kidneys in the pancreas transplant recipients. high levels of calcineurin inhibitors (cni) have been identified as risk factors for decline in kidney function and progression to end-stage renal disease. the objective of this trial is to take subjects who have biopsy proven cni toxicity off of their cni and begin belatacept, which is not a cni. the hypothesis is by switching the pancreas transplant subject with documented cni kidney toxicity to belatacept will slow the progression of chronic kidney disease.

Eligibility criteria:
inclusion criteria: * pancreas transplant alone recipients * ebv igg positive * biopsy proven calcineurin inhibitor toxicity on native kidney biopsy * maintained on a regimen of tacrolimus, sirolimus, mycophenolate exclusion criteria: * ebv igg negative * not maintained on an immunosuppression regimen that contains tacrolimus * unable or unwilling to give informed consent * active infection * history of malignancy post transplant * glomerular filtration rate \< 15 ml/min

Keywords: pancreas transplantation immunosuppression belatacept
comparison of holmium laser enucleation prostatectomy and open transvesical prostatectomy in large prostate

Conditions: Benign Prostatic Hyperplasia

Summary: comparison of holmium laser enucleation prostatectomy and open prostatectomy regarding safety and efficacy in men with prostate larger than 80 grams


Eligibility criteria:
inclusion criteria: * american urological association symptom score of eight or higher, * maximum urinary flow rate of 10ml/s or less, * post void residual urine volume of 50 ml or more, * and a total prostate volume of 80 ml or more in transrectal ultrasound (trus). exclusion criteria: * a previous prostate or urethral surgery * and non-bph related voiding disorders * prostate cancer patients
hallux valgus manual therapy based on global postural reeducation.

Conditions: Hallux Valgus; Hallux Deformity; Foot Deformities

Summary: manual approach of hallux valgus with global postural reeducation.

hallux abducto valgus is a frequent pathology with a prevalence of 30% in women and 13% in men. the tendency is to increase with age. usually, the elected treatment is surgery, as the conservative orthopedic methods are used at the early stages of the pathology. global postural re-education is a manual therapy treatment method through which we can treat lots of pathologies. some investigations demonstrate postural re-education is effective for the treatment of temporomandibular disorders, urinary incontinence, and spine disorders, but there is no scientific evidence that defends the improvement of the symptoms and correction of the angle of the hallux abducto valgus using postural re-education.

Eligibility criteria:
inclusion criteria: * hallux abducto valgus with an angle between 15 - 39º * pain on the medial or plantar face of the forefoot * physical independence to take part in the study. exclusion criteria: * being under hallux abducto valgus treatment. * lower limb surgery. * fracture or disfunction on the lower limb other than hallux valgus which may affect the studied variables.
a comparative analysis of ultrasound's accuracy in diagnosing hc using histopathology as gold standard

Conditions: Hepatocellular Carcinoma

Summary: the study aims to evaluate the accuracy of ultrasound in diagnosing hepatocellular carcinoma (hcc), using histopathology as the gold standard. it addresses hcc's high global incidence and the utility of ultrasound as a non-invasive, cost-effective screening tool. despite ultrasound's accessibility, its diagnostic limitations necessitate further investigation to improve clinical outcomes.


Eligibility criteria:
inclusion criteria: * clinically suspected liver cancer patients undergoing ultrasound examination. * patients undergoing histopathological examination (liver biopsy or resection) for definitive diagnosis. exclusion criteria: - patients with history of liver cancer treatment or inadequate data."
effect and safety of envafolimab combined with endostar/s-1 in second-line of advanced non-small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the trial was a randomized, open-label, multicenter phase ii study of patients with advanced or metastatic nsclc who don't harbor driver genes. the aim is to explore the efficacy and safety of envafolimab combined with endostar/s-1 in second-line treatment of advanced non-small cell lung cancer.

patients with advanced (stage iv. nsclc), after signing informed consent, are screened to meet the admission requirements. all the candidates are not randomly placed in 3 treatment groups (which treatment regimen the patient chooses is determined by the clinical supervisor on a patient-by-case basis).

Eligibility criteria:
inclusion criteria: 1. all patients are histologically or cytologically confirmed stage iv non-small cell lung cancer. genetic testing identifies no driver gene mutations. 2. male or female, age \> 18 years, \< 75 years. 3. patients had not received pd-l1 inhibitors in first-line treatment. 4. kps score ≥ 70 points (ecog score 0-1 points), the expected survival ≥3 months; 5. no dysfunction of major organs. ecg, liver function, renal function, and blood count tests before treatment are normal or basically normal, but must meet the following experimental results: 1. blood routine test: leukocyte wbc≥3.5×109/l; neutrophil count (anc) ≥ 1.5×109/l; platelet (plt) ≥ 80×109/l; 2. blood biochemical test: total bilirubin (tbil) ≤ 1.5 times the upper limit of normal values; alanine aminotransferase (alt/sgpt) and alanine transaminases (ast/sgot) ≤ 2.5 times the normal high value (uln), or ≤ 5 times the upper limit of normal value in patients with liver metastases; serum creatinine (cr) ≤ 1.5 times the upper limit of normal values; c. cardiac function test: 50% of the left ventricular ejection function of the heart \>; 6) the subject has good compliance, and can cooperates with follow-up. exclusion criteria: -
iron overload in african americans

Conditions: Hemochromatosis; Iron Overload

Summary: iron overload (hemochromatosis) is a condition which causes the intestines to take too much iron into the body from food or pills. the extra iron can build up in the liver, heart, joints, pancreas, sex organs, and other organs. patients with iron overload can feel well initially, but the iron will eventually damage organs and may lead to an early death. the condition is believed to be passed down from generation to generation. many studies have been conducted on the condition as it affects caucasian americans, few have addressed the condition in african americans. researchers believe it is important to find out as much as possible about the iron overload in african americans. the goal of this study is to determine the pattern of inheritance of primary iron overload in african american families and to identify the genetic defect causing the condition. the study will use various tests from simple blood testing (transferritin saturation and serum ferritin levels) to complex genetic tests (segregation analysis and polymerase chain reaction \[pcr\]). the tests will help researchers deterimine iron levels in the blood, presence of antigens that may help trace inheritance, and detect changes in genes that are known to cause iron overload in caucasians. the study may not directly benefit the patients participating in it. however, this study may lead to improved methods to diagnose iron overload in the african american population as a whole.

the purpose of this project is to determine the pattern of inheritance of primary iron overload in african american families and to identify the genetic defect. the iron status of index subjects and family members will be determined by measuring transferrin saturation and serum ferritin, and the genetic pattern will be studied with segregation analysis. the chromosomal localization of the iron-loading locus will be pursued by determining hla haplotypes, by testing for hfe gene mutations, by sequencing portions of genes for molecules involved in iron metabolism, by analyzing polymorphisms in these genes by pcr, by employing molecular methods to screen the genome, and by testing for linkage to iron phenotype with lod scores. loci for proteins important in iron metabolism will be examined as candidate genes.

Eligibility criteria:
index subjects as well as male and female first and second degree family members, greater than 5 years of age, of index subjects with iron overload. in some cases, more distant family members will also be studied. no patients less than or equal to 5 years old.

Keywords: genetics hemochromatosis iron metabolism iron storage disorder pedigree iron overload